These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Effect of amino acid replacements, additions and deletions on the antiviral activity of a peptide derived from the HIV-1 GP41 sequence. Jiang S; Lin K Pept Res; 1995; 8(6):345-8. PubMed ID: 8838418 [TBL] [Abstract][Full Text] [Related]
9. An anti-HIV peptide, T22, forms a highly active complex with Zn(II). Tamamura H; Otaka A; Murakami T; Ibuka T; Sakano K; Waki M; Matsumoto A; Yamamoto N; Fujii N Biochem Biophys Res Commun; 1996 Dec; 229(2):648-52. PubMed ID: 8954952 [TBL] [Abstract][Full Text] [Related]
10. [Antiviral compounds: current approaches for development]. Suzutani T; Azuma M Nihon Rinsho; 1993 Jul; 51(7):1907-14. PubMed ID: 8366615 [TBL] [Abstract][Full Text] [Related]
11. Prediction of activity, synthesis and biological testing of anti-HSV active peptides. Jenssen H; Gutteberg TJ; Rekdal Ø; Lejon T Chem Biol Drug Des; 2006 Jul; 68(1):58-66. PubMed ID: 16923027 [TBL] [Abstract][Full Text] [Related]
12. Molecular parameters for the anti-human immunodeficiency virus activity of T22 ([Tyr5,12, Lys7]-polyphemusin II). Otaka A; Tamamura H; Terakawa Y; Masuda M; Koide T; Murakami T; Nakashima H; Matsuzaki K; Miyajima K; Ibuka T Biol Pharm Bull; 1994 Dec; 17(12):1669-72. PubMed ID: 7735216 [TBL] [Abstract][Full Text] [Related]
13. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Wild C; Oas T; McDanal C; Bolognesi D; Matthews T Proc Natl Acad Sci U S A; 1992 Nov; 89(21):10537-41. PubMed ID: 1438243 [TBL] [Abstract][Full Text] [Related]
14. Synthesis of protegrin-related peptides and their antibacterial and anti-human immunodeficiency virus activity. Tamamura H; Murakami T; Horiuchi S; Sugihara K; Otaka A; Takada W; Ibuka T; Waki M; Yamamoto N; Fujii N Chem Pharm Bull (Tokyo); 1995 May; 43(5):853-8. PubMed ID: 7553971 [TBL] [Abstract][Full Text] [Related]
16. NMR structure of mussel mytilin, and antiviral-antibacterial activities of derived synthetic peptides. Roch P; Yang Y; Toubiana M; Aumelas A Dev Comp Immunol; 2008; 32(3):227-38. PubMed ID: 17628674 [TBL] [Abstract][Full Text] [Related]
17. Anti-HIV activity and conformational studies of peptides derived from the C-terminal sequence of SDF-1. Dettin M; Pasquato A; Scarinci C; Zanchetta M; De Rossi A; Di Bello C J Med Chem; 2004 Jun; 47(12):3058-64. PubMed ID: 15163187 [TBL] [Abstract][Full Text] [Related]
18. A comparative study of the solution structures of tachyplesin I and a novel anti-HIV synthetic peptide, T22 ([Tyr5,12, Lys7]-polyphemusin II), determined by nuclear magnetic resonance. Tamamura H; Kuroda M; Masuda M; Otaka A; Funakoshi S; Nakashima H; Yamamoto N; Waki M; Matsumoto A; Lancelin JM Biochim Biophys Acta; 1993 May; 1163(2):209-16. PubMed ID: 8490053 [TBL] [Abstract][Full Text] [Related]
19. CD4(81-92)-based peptide derivatives. Structural requirements for blockade of HIV infection, blockade of HIV-induced syncytium formation, and virostatic activity in vitro. Rausch DM; Lifson JD; Padgett MP; Chandrasekhar B; Lendvay J; Hwang KM; Eiden LE Biochem Pharmacol; 1992 Apr; 43(8):1785-96. PubMed ID: 1575773 [TBL] [Abstract][Full Text] [Related]
20. [3'-Fluoro-deoxythymidine-5-fluorophosphate--an effective inhibitor of reproduction of human immunodeficiency virus in cell cultures]. Arzumanov AA; Diatkina NB; Kukhanova MK; Kraevskiĭ AA; Semchenko FM; Eremin OG; Martynov BI Bioorg Khim; 1993 Oct; 19(10):978-80. PubMed ID: 8274172 [No Abstract] [Full Text] [Related] [Next] [New Search]